Immunosuppression and immunomodulation are valuable therapeutic approaches for managing neuroimmunological diseases. In the present COVID-19 pandemic, clinicians must deal with the question of whether immunotherapy should currently be initiated or discontinued in neurological patients. Uncertainty exists, and different national medical associations have published different recommendations on the extent to which immunotherapies should be continued, monitored, or switched during the current pandemic. In this review, the authors, provide an updated overview that includes current treatment strategies and considers associated COVID-19 risk, but also the potential of immunotherapies to treat COVID-19.
View Article: https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(20)30197-3/fulltext